GLP-1 therapy is particularly considered in patients with a BMI 35 kg/m or those who would benefit from weight loss
The most recent Phase 3 trial showed discontinuation rates of 12-18% due to adverse events, higher than existing GLP-1 medications
Market Report Scope GLP-1 Receptor Agonist Market Report Coverage Uncover macros and micros vetted on 75+ parameters: Get instant access to report GLP-1 Receptor Agonist Industry News In July 2025, PolyPid Ltd
If Wegovy contraindications exist, genetic testing through PlexusDx reveals your peptide pathway strengths and weaknesses, guiding selection between semaglutide, tirzepatide, microdose protocols, or dual-compound formulas
14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7%)
may sometimes lead to the need for hemodialysis Thyroid C-Cell Tumor: Trouble swallowing, hoarseness, a lump or swelling in your neck, or shortness of breath (see black box warning below) Pancreatitis: Severe pain in your abdomen or back that will not go away Acute gallbladder disease - Pain in the middle or right upper stomach, fever, white parts of your eyes turn yellow or skin turns yellow, nausea/vomiting
